EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer’s disease

Barbara Morgado, Hans-Wolfgang Klafki, Chris Bauer, Katharina Waniek, Hermann Esselmann, Oliver Wirths, Niels Hansen, Ingolf Lachmann, Dirk Osterloh, Johannes Schuchhardt, Jens Wiltfang

European Archives of Psychiatry and Clinical Neuroscience · 2025-12 · 275 (8) · 2215-2227

DOI: 10.1007/s00406-023-01751-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Archives of Psychiatry and Clinical Neuroscience, online erschienen am 06.02.2024. Verfasst von Barbara Morgado und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG), Georg-August University, Von-Siebold Strasse 5, 37075, Goetti…. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, tau Proteins, Immunoprecipitation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, Freistaat Sachsen, Georg-August-Universität Göttingen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Aβ42/40 ratio and the concentration of phosphorylated Tau181 in blood plasma represent attractive biomarkers for Alzheimer's disease. As a means for reducing potential matrix effects, which may interfere with plasma immunoassays, we have previously developed a pre-analytical sample workup by semi-automated immunoprecipitation. Here we test the compatibility of pre-analytical immunoprecipitations with automated Aβ1-40, Aβ1-42 and phosphorylated Tau181 immunoassays on the Lumipulse platform and compare the diagnostic performance of the respective immunoprecipitation immunoassay approaches with direct plasma measurements. 71 participants were dichotomized according to their Aβ42/40 ratios in cerebrospinal fluid into the diagnostic groups amyloid-positive ( n = 32) and amyloid-negative ( n = 39). The plasma Aβ1-42/1-40 ratio and phosphorylated Tau181 levels were determined on the Lumipulse G600II platform (Fujirebio) by direct measurements in EDTA–plasma or after Aβ- or Tau-immunoprecipitation, respectively. Pre-analytical immunoprecipitation of Aβ turned out to be compatible with the Lumipulse Aβ assays and resulted in a numerical, yet statistically not significant increase in the area under the ROC curve for plasma Aβ1-42/1-40. Additionally, we observed a significant increase in the standardised effect size (Cohen’s D). Pre-analytical immunoprecipitation of Tau resulted in increased differences between the diagnostic groups in terms of median and mean phosphorylated Tau 181 levels. Furthermore, we observed a greater Cohen’s d ( p < 0.001) and a larger area under the ROC curve ( p = 0.038) after Tau-IP. Our preliminary findings in a small, preselected sample indicate that pre-analytical immunoprecipitation may have the potential to improve the diagnostic performance of plasma biomarker immunoassays for Aβ1-42/1-40 and phosphorylated Tau181 to predict brain amyloid deposition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-Peptidestau ProteinsImmunoprecipitationPeptide FragmentsHumansMaleFemaleAgedImmunoassayBiomarkersPhosphorylationAged, 80 and overMiddle AgedROC Curve

Stichwörter der Autor:innen

Alzheimer’s diseaseAmyloid betaBiomarkerBlood plasmaTau

Substanzen

Amyloid beta-Peptidestau ProteinsPeptide Fragmentsamyloid beta-protein (1-42)Biomarkersamyloid beta-protein (1-40)MAPT protein, human

Autor:innen und Institutionen

  • Department of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG), Georg-August University, Von-Siebold Strasse 5, 37075, Goettingen, Germany. barbara.marcosmorgado@med.uni-goettingen.de.
  • Department of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG), Georg-August University, Von-Siebold Strasse 5, 37075, Goettingen, Germany.
  • MicroDiscovery GmbH, Marienburger Strasse 1, 10405, Berlin, Germany.
  • Roboscreen GmbH, Hohmannstrasse 7, 04129, Leipzig, Germany.
  • Department of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG), Georg-August University, Von-Siebold Strasse 5, 37075, Goettingen, Germany. Jens.Wiltfang@med.uni-goettingen.de.
  • German Center for Neurodegenerative Diseases (DZNE), 37075, Goettingen, Germany. Jens.Wiltfang@med.uni-goettingen.de.

Förderung

  • Bundesministerium für Bildung und Forschung
  • Freistaat Sachsen
  • Georg-August-Universität Göttingen

Zitieren

APA

Morgado, B., Klafki, H. W., Bauer, C., Waniek, K., Esselmann, H., Wirths, O., Hansen, N., Lachmann, I., Osterloh, D., Schuchhardt, J., & Wiltfang, J. (2025). Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer’s disease. European Archives of Psychiatry and Clinical Neuroscience, 275(8), 2215-2227. https://doi.org/10.1007/s00406-023-01751-2

Vancouver

Morgado B, Klafki HW, Bauer C, Waniek K, Esselmann H, Wirths O, et al. Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer’s disease. European Archives of Psychiatry and Clinical Neuroscience. 2025;275(8):2215-2227. doi:10.1007/s00406-023-01751-2

BibTeX
@article{Morgado2025,
  author = {Morgado, Barbara and Klafki, Hans-Wolfgang and Bauer, Chris and Waniek, Katharina and Esselmann, Hermann and Wirths, Oliver and Hansen, Niels and Lachmann, Ingolf and Osterloh, Dirk and Schuchhardt, Johannes and Wiltfang, Jens},
  title = {Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer’s disease},
  journal = {European Archives of Psychiatry and Clinical Neuroscience},
  year = {2025},
  volume = {275},
  number = {8},
  pages = {2215--2227},
  doi = {10.1007/s00406-023-01751-2}
}
Kostenlos starten →